Stacey Lynn Zeigler, PT | |
540 Stone Rd, Harrisville, NY 13648-3244 | |
(315) 543-7130 | |
Not Available |
Full Name | Stacey Lynn Zeigler |
---|---|
Gender | Female |
Speciality | Physical Therapist - Geriatrics |
Location | 540 Stone Rd, Harrisville, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1700098456 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2251G0304X | Physical Therapist - Geriatrics | 014376 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Stacey Lynn Zeigler, PT 540 Stone Rd, Harrisville, NY 13648-3244 Ph: (315) 543-7130 | Stacey Lynn Zeigler, PT 540 Stone Rd, Harrisville, NY 13648-3244 Ph: (315) 543-7130 |
News Archive
Cancer Research UK scientists have discovered a new gene that protects against lung cancer, according to a study published in the journal PNAS.
University of Texas at Dallas researchers have developed a promising method for remotely stimulating activity in deep brain regions, advancing understanding of how molecules act in the brain and paving the way for better cancer treatments and therapies for other diseases.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
According to the latest research sexually transmitted infections continue to flourish in the UK and have in fact risen for the 10th successive year.
Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.
› Verified 4 days ago